Time to revisit the classification of hemophilia: if it ain't broke, don't fix it!
- PMID: 37330266
- DOI: 10.1016/j.jtha.2023.04.009
Time to revisit the classification of hemophilia: if it ain't broke, don't fix it!
Conflict of interest statement
Declaration of competing interests G.Y. has received honoraria from Apcintex, BioMarin, CSL Behring, Genentech/Roche, Hema Biologics/LFB, Novo Nordisk, Octapharma, Pfizer, Sanofi Genzyme, Spark, and Takeda and funds for research support from Genentech/Roche and Takeda. M.M. has received honoraria for lecturing and grant reviewing as well as is on advisory committee of NovoNordisk, Takeda, Grifols, and Sanofi.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
